High public expectations for checkpoint inhibitor therapy need to be tempered by the reality of low absolute numbers of cancer patients who benefit from them, US researchers say. While almost half of cancer patients (46.3%) are now potentially eligible for immune checkpoint inhibitor treatment, only 12.46% of patients are likely to be responders, according to ...
The sobering reality of checkpoint inhibitors: only 13% of cancer patients are responders
By Michael Woodhead
8 May 2019